Comparison of Analgesic Efficacy and Occurrence of Emesis Among Different Background Infusion and Bolus Administration Regimens of Fentanyl Based Intravenous Patient-controlled Analgesia in Patients After Laparoscopic Assisted Gastrectomy - a Randomized Blind Study -

NCT ID: NCT01863355

Last Updated: 2013-05-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

225 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fentanyl based intravenous patient controlled analgesia(PCA)is popular method for postoperative pain control, but information regarding optimal dose of fentanyl in IV PCA is currently lacking. We thus determine appropriate dose of fentanyl (bolus dose and background infusion rate) for effective pain control with minimal side effects such as nausea and vomiting

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

The Patients With Gastric Cancer Who Are Scheduled to Receive Laparoscopy Assisted Gastrectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

B0

(basal rate 0cc/hr, bolus 3cc, lockout time 10min)

Group Type EXPERIMENTAL

B0 group: bolus 0.6mcg/kg without background infusion

Intervention Type DRUG

BL

(basal rate 1cc/hr, bolus 2cc, lockout time 10min)

Group Type ACTIVE_COMPARATOR

BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr

Intervention Type DRUG

BH

(basal rate 2cc/hr, bolus 1cc, lockout time 10min)

Group Type ACTIVE_COMPARATOR

BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

B0 group: bolus 0.6mcg/kg without background infusion

Intervention Type DRUG

BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr

Intervention Type DRUG

BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fentanyl based intraveonus patient controlled analgesia Fentanyl based intraveonus patient controlled analgesia Fentanyl based intraveonus patient controlled analgesia

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 20 and 70
* ASA class I and II
* Gastric cancer patients who are scheduled to receive laparoscopic gastrectomy

Exclusion Criteria

* Cardiovascular disease(uncontrolled hypertension, unstable angina, congestive heart failure, etc.)
* Renal failure
* Liver failure
* Chronic drug or alcohol abuser
* Anti-cancer chemotherapy
* Chronic opioid use
* Use of antiemetics within 24hrs for nausea and vomiting
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yonsei University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Severance Hospital, Yonsei University Health System

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kwan-woong Choi

Role: CONTACT

(82) 2-2227-4613

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kwan-woong Choi

Role: primary

(82) 2-2227-4613

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4-2013-0176

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.